1. What is the mechanism by which olaparib and rucaparib increase serum creatinine?

2. Which of the following is a recommended antiemetic regimen for olaparib?

3. Which PARP inhibitor(s) has/have been approved by the United States Food and Drug Administration (FDA) for use in the first-line maintenance setting in newly diagnosed ovarian cancer?

« Return to Activity